About the talk
CBD might be the well-known cannabinoid regularly extracted from hemp plants, but it is not the only one. Minor cannabinoids, such as CBG and CBC have medicinal properties of their own. While these cannabinoids are typically in much lower concentrations within the plant, they can still be isolated and purified using methods like flash or supercritical fluid chromatography (SFC). The isolation of these cannabinoids, such that adequate purity is achieved, is paramount for better understanding what benefits these cannabinoids impart. In addition, techniques like SFC can help clean up mother liquors to ensure that all of the gold is extracted from the garbage. In this panel, we examine why these minor cannabinoids present such an exciting new development for the industry, how to extract and purify them, and what the future may look like as a result.
00:37 The minor cannabinoids
14:11 Cis–trans isomerism
19:41 Biopharmaceutical company
24:17 Simulated moving bed
29:11 Cosigner events
34:05 Continuous system
38:07 Liquid chromatography
Dr. King’s research and teaching focus is in the area of chemical separations, particularly in the use of sub- and supercritical fluids for chemical processing. Research is conducted to develop environmentally-benign methodology using compressed carbon dioxide and/or water as media for conducting extractions and reactions of natural/agricultural products, CO2 – based cleaning technology, as well as application to materials modification. These efforts have resulted in approximately 250 publications and 3 patents to date and many national/international presentations. A current research focus is to optimize the use of hot compressed water as a selective extraction agent or medium in which to process biomass. Using the above approach, coupled unit processes are developed with respect to yielding a sustainable “green” process, which has been optimized with respect to thermodynamics and mass transfer principles. Experimental approaches involve the measurement of high pressure phase equilibrium, solute solubility measurements in compressed fluids, and the use of chromatographic methods for physicochemical properties determination.View the profile
Currently, I work for Hybrid Tech as the Process Lead as well as Spektrum Cannabis Technologies as a Senior Chemist, located in Portland, OR. I worked for 3 years as an industrial hygiene chemist for OSHA, focusing on chromatography methods (GC, LC, and IC) to identify and quantify hazardous organic and inorganic substances collected by OSHA compliance officers. I graduated from the chemistry doctoral program at Indiana University, where my major was in inorganic chemistry and my minor in analytical chemistry. Before switching to inorganic chemistry I previously worked in an analytical chemistry lab for 2 years working on glow-discharge optical emission spectroscopy and instrumentation design. Most of my graduate career I worked in a computational and experimental inorganic lab where I combined both DFT calculations with experimental data to learn the fundamentals and applications of catalysis, mechanisms, and electron-transfer processes. My experimental experience involves inorganic and organic synthesis, electrochemistry, NMR, FT-IR, UV-Vis, mass spectrometry techniques (GC-MS and LC-MS), and atomic spectroscopy. I have aided in the instruction of undergraduate courses since 2008.View the profile
Rob Wirtz enjoys fast-paced sports and is a student of the entrepreneurial mindset. He brought his talents and his skills for team building to the Cannabis industry and is quickly making an impact.View the profile
John A. MacKay earned his B.A. in Chemistry at the St. Lawrence University. He also earned his Ph.D. At the University of Vermont, where he focused on Inorganic Chemistry and on the synthesis of cancer fighting compounds. After working in teaching positions at the University of Vermont, Lyndon State College, and Davidson College, John went on to join Waters Corporation in 1983.View the profile
Good afternoon. So this is a session where we're looking at some of the other minor cannabinoids and I'm assuming they're calling the minor cannabinoids just because on one part they didn't have the genetics of the of the original. You know, I will call it a cottage industry genetics on manufacturing things with more THC. versus, you know, some of them are control genetics that are happening now with a gene, splicing and everything else. So from that side of the point, you can be making more compounds. That, that CBG
is the major 1 verses saying it's a minor one, you will have more people making plants. It genetically will emphasize a synthase that makes other cannabinoids to thcv or some of the other ones that are that are possible. So it's it's not so much looking at what, what we now term is minor. It's just more of looking at the rest of the cannabinoids that our bio synthesized or place in a biopharma world where you're trying to emulate, what a plant is doing.